Risk factors of hyperprolactinemia induced by risperidone and olanzapine and their correlations with plasma glucose and lipids

General Psychiatry
Sidi HeHuafang Li

Abstract

Hyperprolactinemia is a common adverse reaction in patients with schizophrenia who take antipsychotic drugs; it often leads to treatment non-compliance in patients and has an adverse effect on their prognosis. This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Patients with schizophrenia were divided into two groups: 264 patients who were taking RIS and 175 patients who were taking OLZ. These two groups were further divided according to serum PRL levels: an elevated PRL group (>30 ng/mL) and a normal PRL group (PRL ≤30 ng/mL). The demographics, medication dosage, fasting plasma glucose, total cholesterol and triglycerides were compared in the two groups. Logistic regression analysis was performed to explore the risk factors of elevated PRL levels. Compared with the OLZ group, the RIS group had a greater number of patients with elevated PRL (155/264 vs 58/175). Either the RIS or the OLZ group, the proportion of elevated PRL was greater in female patients (RIS: χ2=6.76, p=0.009; OLZ: χ2=12.98, p<0.001) and with higher doses of the related drugs (RIS: U=-3.73, p<0.001; OLZ: U=-2.31, p=0.021...Continue Reading

References

Jan 13, 2001·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·A E KearnsG H Daniels
Apr 8, 2003·The Journal of Clinical Endocrinology and Metabolism·Charlotte LingHåkan Billig
Dec 10, 2003·Archives of General Psychiatry·Patrick F SullivanMichael C Neale
May 11, 2005·Biochemical and Biophysical Research Communications·Louise NilssonHåkan Billig
Jun 26, 2007·Diabetes, Obesity & Metabolism·T BrandebourgN Ben-Jonathan
Mar 13, 2008·The Journal of Clinical Endocrinology and Metabolism·Jennifer S LeeSteven R Cummings
Aug 16, 2008·Journal of Psychopharmacology·Peter Fitzgerald, Timothy G Dinan
Feb 3, 2009·The British Journal of Psychiatry : the Journal of Mental Science·Magali HaasVivek Kusumakar
Mar 25, 2009·Endocrinology·Robert L Sorenson, Todd C Brelje
Jan 1, 2014·Progress in Molecular Biology and Translational Science·Yao Huang, Yongchang Chang
Nov 20, 2016·The Lancet. Psychiatry·Anita Riecher-Rössler
Jan 23, 2018·Journal of Child and Adolescent Psychopharmacology·Lei XiaXiang-Yang Zhang
Jun 27, 2019·Diabetes & Metabolic Syndrome·Hatice OzisikSevki Cetinkalp

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02640911

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here